恶性T细胞通过细胞因子介导的JAK/STAT信号诱导皮肤T细胞淋巴瘤皮肤屏障缺陷
本研究探讨皮肤T细胞淋巴瘤(CTCL)中恶性T细胞导致皮肤屏障缺陷的机制,发现皮损区经表皮水分丢失增加且丝聚蛋白与丝聚蛋白-2表达降低,恶性T细胞分泌IL-13、IL-22及制瘤素M等细胞因子激活STAT3信号并下调角质形成细胞中丝聚蛋白表达,JAK1抑制剂托法替尼可增加蕈样肉芽肿患者皮损中丝聚蛋白表达。
要点
- CTCL皮损中TOX阳性T细胞邻近区域经表皮水分丢失增加且丝聚蛋白与丝聚蛋白-2表达降低
- 恶性T细胞分泌IL-13、IL-22及制瘤素M等细胞因子激活STAT3信号并下调丝聚蛋白表达
- JAK1抑制剂托法替尼可增加蕈样肉芽肿患者皮损中丝聚蛋白表达
核心结论
- 恶性T细胞通过JAK1/STAT3依赖机制分泌细胞因子诱导皮肤屏障缺陷,临床级JAK抑制剂可 largely abrogate 恶性T细胞对皮肤屏障蛋白的负效应。
研究设计与样本
- 本研究为实验研究,纳入CTCL患者皮损样本,采用人角质形成细胞和重建人上皮模型进行体外实验。
主要发现
- CTCL皮损中TOX阳性T细胞邻近区域经表皮水分丢失增加,丝聚蛋白和丝聚蛋白-2表达降低。
- 恶性T细胞分泌的IL-13、IL-22和制瘤素M等细胞因子激活STAT3信号并下调人角质形成细胞和重建人上皮中丝聚蛋白和丝聚蛋白-2表达。
- 靶向这些细胞因子/受体的抗体混合物、siRNA介导的JAK1/STAT3敲低及JAK1抑制剂可逆转丝聚蛋白抑制。
- 临床批准的JAK抑制剂托法替尼治疗可增加蕈样肉芽肿患者皮损中丝聚蛋白表达。
临床怎么用
- 作者认为,临床级JAK抑制剂为晚期疾病伴皮肤屏障受损的CTCL患者提供了新的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA-mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.
引用
- Gluud M, Pallesen EMH, Buus TB, et al. Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma. Blood. 2023. PMID: 36122387. doi:10.1182/blood.2022016690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。